Nuvation Bio Q4 net loss $13.8M ($0.06/shr); cash $611.2M; pipeline advances for NUV-868 and NUV-1511

Nuvation Bio Inc.

2023-FY EPS reported -$0.35

Q4 net loss $13.8M ($0.06/shr); full-year net loss $75.8M, improved from $104.2M in 2022.
Cash, equivalents and marketable securities $611.2M at Dec 31, 2023.
Completed NUV-868 Phase 1 monotherapy, determined MTD; Phase 1b combo studies (olaparib/enzalutamide) ongoing.
FDA cleared IND for NUV-1511, first DDC candidate; Phase 1/2 study expected to start H1 2024.
Appointed Dr. Robert Mashal to Board of Directors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Nuvation Bio Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net loss of $13.8 million, or $(0.06) per share, EPS $(0.06) per share.

Period: the fourth quarter and full year ended December 31, 2023
Net income: net loss of $13.8 million, or $(0.06) per share
EPS: $(0.06) per share
Result: reported results

Exact text from the filing

Nuvation Bio reported a net loss of $13.8 million, or $(0.06) per share.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuvation Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-053575

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.